Mirati Therapeutics, Inc.
MRTX · NASDAQ
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Market Cap | $3 | $2 | $2 | $3 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $3 | $2 | $2 | $2 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 19.8% | 91% | 667.3% | – |
| Gross Profit | $0 | $0 | $0 | -$0 |
| % Margin | 84.5% | 90.6% | 88.6% | -15,085.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -1,042.3% | -1,359.8% | -2,603.6% | -22,218.7% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -987.2% | -1,292.3% | -2,575.5% | -21,678.3% |
| EPS Diluted | -2.49 | -3.04 | -3.02 | -3.51 |
| % Growth | 18.1% | -0.7% | 14% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |